Vaccines, Blood & Biologics

MenHibrix

STN: BL 125363/0
Proper Name: Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine
Trade Name: MenHibrix
Manufacturer: GlaxoSmithKline Biologicals
Indication:

  • Indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b for children 6 weeks of age through 18 months of age.

Supporting Documents

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002

Page Last Updated: 01/22/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.